EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial

Adam B Weiner iD, James A Proudfoot, Mamdouh Aker, Michelle Cardenas, Samantha Gonzalez iD, Eileen Kelly, Elai Davicioni, Anthony E Sisk, Wayne G Brisbane iD, Leonard S Marks iD

JCO Precision Oncology · 2025-09 · (9)

DOI: 10.1200/po-25-00535 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025-09. Verfasst von Adam B Weiner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A biomarker to help predict outcomes after prostate cancer (PCa) focal therapy would be of considerable interest. We sought to assess the association between treatment failure after focal therapy and the Decipher score, a tumor-based genomic classifier (GC). MATERIALS AND METHODS We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643 ) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland cryoablation of the prostate (2017-2021; n = 108). Pretreatment biopsy tissue was subjected to transcriptomic profiling to generate GC scores. The primary outcome was the association between GC-low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorHumansMaleAgedMiddle AgedCryosurgeryGenomicsTreatment FailureMagnetic Resonance Imaging

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
  • Veracyte, Inc. San Diego, CA.
  • Department of Pathology, University of California- Los Angeles, Los Angeles, CA.

ORCID-Profile: Adam B Weiner, Samantha Gonzalez, Wayne G Brisbane, Leonard S Marks

Förderung

  • NCI NIH HHS

Zitieren

APA

Weiner, A. B., Proudfoot, J. A., Aker, M., Cardenas, M., Gonzalez, S., Kelly, E., Davicioni, E., Sisk, A. E., Brisbane, W. G., & Marks, L. S. (2025). Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial. JCO Precision Oncology. https://doi.org/10.1200/po-25-00535

Vancouver

Weiner AB, Proudfoot JA, Aker M, Cardenas M, Gonzalez S, Kelly E, et al. Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial. JCO Precision Oncology. 2025. doi:10.1200/po-25-00535

BibTeX
@article{Weiner2025,
  author = {Weiner, Adam B and Proudfoot, James A and Aker, Mamdouh and Cardenas, Michelle and Gonzalez, Samantha and Kelly, Eileen and Davicioni, Elai and Sisk, Anthony E and Brisbane, Wayne G and Marks, Leonard S},
  title = {Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00535}
}
Kostenlos starten →